Patents by Inventor Martin Winn

Martin Winn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
    Publication number: 20100152179
    Abstract: A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-?-hydroxysteroid dehydrogenase Type 1 enzyme activity.
    Type: Application
    Filed: August 21, 2008
    Publication date: June 17, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: R. Scott Bitner, Kaitlin E. Browman, Michael E. Brune, Yixian Chen, Jurgen Dinges, Karla Drescher, Peer Jacobson, Hwan-soo Jae, Ravi Kurukulasuriya, James T. Link, David J. Madar, Jyoti R. Patel, Marina A. Pliushchev, Jeffrey J. Rohde, Lynne E. Rueter, Qi Shuai, Bryan K. Sorensen, Jiahong Wang, Karsten M. Wicke, Martin Winn, Dariusz Wodka, Vince Yeh, Hong Yong
  • METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME
    Publication number: 20090192141
    Abstract: The present invention relates to inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.
    Type: Application
    Filed: February 20, 2009
    Publication date: July 30, 2009
    Applicant: ABBOTT LABORATORIES
    Inventors: R. Scott Bitner, Kaitlin E. Browman, Michael E. Brune, Steven Fung, Peer B. Jacobson, Lynne E. Rueter, Marina I. Strakhova, Jiahong Wang, James T. Link, Yixian Chen, Hwan-soo Jae, Jyoti R. Patel, Marina A. Pliushchev, Jeffrey J. Rohde, Qi Shuai, Bryan K. Sorensen, Martin Winn, Dariusz Wodka, Hong Yong
  • INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME
    Publication number: 20090192198
    Abstract: The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.
    Type: Application
    Filed: February 20, 2009
    Publication date: July 30, 2009
    Applicant: Abbott Laboratories
    Inventors: R. Scott Bitner, Kaitlin E. Browman, Michael E. Brune, Steven Fung, Peer B. Jacobson, Lynne E. Rueter, Marina I. Strakhova, Jiahong Wang, Jyoti R. Patel, Qi Shuai, James T. Link, Jeffrey J. Rohde, Jurgen Dinges, Bryan K. Sorensen, Martin Winn, Hong Yong, Vince S. Yeh
  • Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
    Publication number: 20090131434
    Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
    Type: Application
    Filed: January 19, 2009
    Publication date: May 21, 2009
    Applicant: ABBOTT LABORATORIES
    Inventors: Michael E. Brune, Peer B. Jacobson, James T. Link, Jyoti R. Patel, Jeffrey J. Rohde, Qi Shuai, Martin Winn, Vince S. Yeh, Hong Yong
  • Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
    Patent number: 7511175
    Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
    Type: Grant
    Filed: January 5, 2006
    Date of Patent: March 31, 2009
    Assignee: Abbott Laboratories
    Inventors: Jyoti R. Patel, Qi Shuai, James T. Link, Jeffrey J. Rohde, Jurgen Dinges, Bryan K. Sorensen, Martin Winn, Hong Yong, Peer B. Jacobson, Michael E. Brune
  • TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
    Publication number: 20090054426
    Abstract: A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-?-hydroxysteroid dehydrogenase Type 1 enzyme activity.
    Type: Application
    Filed: August 21, 2008
    Publication date: February 26, 2009
    Applicant: ABBOTT LABORATORIES
    Inventors: R. Scott Bitner, Kaitlin E. Browman, Michael E. Brune, Yixian Chen, Jurgen Dinges, Karla Drescher, Peer Jacobson, Hwan-soo Jae, Ravi Kurukulasuriya, James T. Link, David J. Madar, Jyoti R. Patel, Marina A. Pliushchev, Jeffrey J. Rohde, Lynne E. Rueter, Qi Shuai, Bryan K. Sorensen, Jiahong Wang, Karsten M. Wicke, Martin Winn, Dariusz Wodka, Vince Yeh, Hong Yong
  • Endothelin antagonists
    Patent number: 7365093
    Abstract: A compound of the formula (I): or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.
    Type: Grant
    Filed: February 23, 2005
    Date of Patent: April 29, 2008
    Assignee: Abbott Laboratories
    Inventors: Martin Winn, Steven A. Boyd, Charles W. Hutchins, Hwan-Soo Jae, Andrew S. Tasker, Thomas W. von Geldern, Jeffrey A. Kester, Bryan K. Sorensen, Bruce G. Szczepankiewicz, Kenneth J. Henry, Gang Liu, Steven J. Wittenberger, Steven A. King
  • Endothelin antagonists
    Patent number: 7208517
    Abstract: A compound of the formula (I): or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, a method of antagonizing endothelin, methods for the inhibition of bone metastases, methods for the prevention of growth of new metastases, methods for the inhibition of bone turnover, and methods for the prevention of bone loss in patients, including cancer patients, using an endothelin ET-A receptor antagonist.
    Type: Grant
    Filed: August 31, 2000
    Date of Patent: April 24, 2007
    Assignee: Abbott Labortories
    Inventors: Martin Winn, Steven A. Boyd, Charles W. Hutchins, Hwan-Soo Jae, Andrew S. Tasker, Thomas W. von Geldern, Jeffrey A. Kester, Bryan K. Sorensen, Bruce G. Szczepankiewicz, Kenneth J. Henry, Gang Liu, Steven J. Wittenberger, Steven A. King, Todd J. Janus, Robert J. Padley
  • Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
    Publication number: 20060281773
    Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
    Type: Application
    Filed: January 5, 2006
    Publication date: December 14, 2006
    Inventors: Jyoti Patel, Qi Shuai, James Link, Jeffrey Rohde, Jurgen Dinges, Bryan Sorensen, Martin Winn, Hong Yong, Vince Yeh
  • Endothelin antagonists
    Publication number: 20060229280
    Abstract: A compound of the formula (I): or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.
    Type: Application
    Filed: February 23, 2005
    Publication date: October 12, 2006
    Inventors: Martin Winn, Steven Boyd, Charles Hutchins, Hwan-Soo Jae, Andrew Tasker, Thomas von Geldern, Jeffrey Kester, Bryan Sorensen, Bruce Szczepankiewicz, Kenneth Henry, Gang Liu, Steven Wittenberger, Steven King
  • Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
    Publication number: 20050277647
    Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.
    Type: Application
    Filed: April 29, 2005
    Publication date: December 15, 2005
    Inventors: James Link, Yixian Chen, Hwan-Soo Jae, Jyoti Patel, Marina Pliushchev, Jeffrey Rohde, Qi Shuai, Bryan Sorensen, Martin Winn, Dariusz Wodka, Hong Yong
  • Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application
    Publication number: 20050261302
    Abstract: The present invention relates to the use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment or prophylactically treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions mediated by excessive glucocorticoid action.
    Type: Application
    Filed: April 28, 2005
    Publication date: November 24, 2005
    Inventors: Ethan Hoff, James Link, Marina Pliushchev, Jeffrey Rohde, Martin Winn
  • Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
    Publication number: 20050250768
    Abstract: The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immune diseases, to pharmaceutical compositions containing these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.
    Type: Application
    Filed: August 20, 2004
    Publication date: November 10, 2005
    Inventors: James Link, Gang Liu, ZhongHua Pei, Tom Geldern, Martin Winn, Zhili Xin, Steven Boyd, Gui-Dong Zhu, Jennifer Freeman, Indrani Gunawardana, Michael Staeger, Hwan-Soo Jae, John Lynch, Sheldon Wang
  • Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application
    Publication number: 20050245532
    Abstract: The present invention relates to the use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment or prophylactically treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions mediated by excessive glucocorticoid action.
    Type: Application
    Filed: April 29, 2004
    Publication date: November 3, 2005
    Inventors: Ethan Hoff, James Link, Marina Pliushchev, Jeffrey Rohde, Martin Winn
  • Inhibitors of the 11-beta-hydroxysteroid dehydrogenaseType 1 enzyme and their therapeutic application
    Publication number: 20050245533
    Abstract: The present invention relates to the use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment or prophylactically treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions mediated by excessive glucocorticoid action.
    Type: Application
    Filed: October 14, 2004
    Publication date: November 3, 2005
    Inventors: Ethan Hoff, James Link, Marina Pliushchev, Jeffrey Rohde, Martin Winn
  • Endothelin antagonists
    Patent number: 6946481
    Abstract: A compound of the formula (I): or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.
    Type: Grant
    Filed: October 8, 2002
    Date of Patent: September 20, 2005
    Assignee: Abbott Laboratories
    Inventors: Martin Winn, Steven A. Boyd, Charles W. Hutchins, Hwan-Soo Jae, Andrew S. Tasker, Thomas W. von Geldern, Jeffrey A. Kester, Bryan K. Sorensen, Bruce G. Szczepankiewicz, Kenneth J. Henry, Gang Liu, Steven J. Wittenberger, Steven A. King
  • Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
    Patent number: 6878700
    Abstract: The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immunune diseases, to pharmaceutical compositions containing these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.
    Type: Grant
    Filed: March 31, 2000
    Date of Patent: April 12, 2005
    Assignee: Abbott Laboratories
    Inventors: James Link, Gang Liu, ZhongHua Pei, Tom von Geldern, Martin Winn, Zhili Xin, Steven A. Boyd, Gui-Dong Zhu, Jennifer C. Freeman, Indrani W. Gunawardana, Michael A. Staeger, Hwan-Soo Jae, John K. Lynch, Sheldon Wang
  • Remote tracing of data processing nodes in an asynchronous messaging network
    Patent number: 6836881
    Abstract: Remote tracing from a local data processing node of the execution of a process within an application program running on a remote data processing node in a distributed data processing network. The application program includes its own local trace facility and the nodes communicate by asynchronous messaging via mailboxes. Each node includes process-provate interrupt handling means for indicating the presence of a command for the respective process in the mailboxes.
    Type: Grant
    Filed: March 26, 2001
    Date of Patent: December 28, 2004
    Assignee: International Business Machines Corporation
    Inventors: Stephen John Beynon, Brian Kenneth Mihell, Andrew Mark Swinson, Geoffrey Martin Winn
  • Glucocorticoid receptor antagonists for treatment of diabetes
    Patent number: 6593480
    Abstract: Compounds of formula I are useful for treating type II diabetes, obesity, hyperglycemia, inadequate glucose clearance, hyperinsulinemia, hypertriglyceridemia, and high-circulating glucocorticoid levels, preparations of the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: July 15, 2003
    Assignee: Abbott Laboratories
    Inventors: Philip R. Kym, Benjamin C. Lane, John K. Pratt, Tom Von Geldern, Martin Winn, Jehrod Brenneman, Jyoti R. Patel, David L. Arendsen, Irini Akritopoulou-Zanze, Kimba L. Ashworth, Kresna Hartandi
  • Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
    Patent number: RE39197
    Abstract: The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immune diseases, to pharmaceutical compositions comprising these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.
    Type: Grant
    Filed: August 29, 2002
    Date of Patent: July 18, 2006
    Assignee: Abbott Laboratories
    Inventors: James T. Link, Gang Liu, Zhonghua Pei, Tom von Geldern, Martin Winn, Zhili Xin